The analysis of Pro-Cure’s gene profile data has also shown cancer stem cells targets with so called “second medical use” opportunities. These are intracellular or extracellular proteins which are already targeted by existing, clinically validated therapeutic drugs. These offer immediate partnering opportunities, provide insight relating to specific targeting pharmacophores and are near-market.